VVT Med Signs $3.7 Million Distribution Agreement in India, Achieves European Sales Milestone and Announces Proposed Debt Settlement

Executive Summary

• VVT Med signed a five‑year CAD $3.7 million distribution agreement with Medworks India for its ScleroSafe™ device, initiating commercial rollout in the Indian varicose‑vein market.
• The company reported completion of 150 ScleroSafe™ treatments in North Macedonia, demonstrating efficacy under CE certification and driving recurring orders in Europe.
• VVT Med announced a proposed debt settlement involving issuance of up to 1,745,151 common shares at CAD $0.31 per share (plus 320,000 shares for services) to retire approximately CAD $720k of indebtedness, subject to TSXV approval.

Key Details

• Distribution Agreement – India
• Five‑year term starting September 5 2025.
• Total purchase commitment: CAD $3.7 million of ScleroSafe™ units.
• “Buy & Pay” component: CAD $1.85 million, with early termination provisions.

• Initial stocking order already placed; rollout and physician adoption underway.

• European Clinical Milestone

• 150 ScleroSafe™ treatments completed in North Macedonia via exclusive representative Promedika.
• Procedures provide substantive evidence of product efficacy under EU CE certification.

• Recurring orders confirmed; additional replenishment orders expected as adoption expands across the EEA.

• Proposed Debt Settlement & Shares for Services

• Issue of 320,000 common shares at a deemed price of CAD $0.56 per share as compensation for advisory services related to public listing.
• Proposed settlement of up to CAD $720,197 debt through issuance of up to 1,745,151 common shares at market price CAD $0.31 per share.
• Shares subject to a statutory hold period of four months and one day.

• Completion conditional on definitive agreements and final TSXV approval.

• Regulatory & Approval Notes

• ScleroSafe™ received CDSCO (India) regulatory approval in 2022.
• CE marking enables sales throughout the European Economic Area.

Notable Quotes

“This partnership underscores Medworks India's confidence in the commercial potential of ScleroSafe™. It is another important step in our global commercialization strategy and reflects the accelerating demand for our innovative NT‑NT venous‑care solution,” – Erez Tetro, CEO, VVT Med Inc.

“ScleroSafe is my preferred technology for treating varicose veins, particularly in complex cases such as ulcers, recurrences, and advanced disease,” – Dr. Sasko Nikolov, Interventional Cardiologist